Article thumbnail

Curcumin-Loaded Apotransferrin Nanoparticles Provide Efficient Cellular Uptake and Effectively Inhibit HIV-1 Replication In Vitro

By Upendhar Gandapu, R. K. Chaitanya, Golla Kishore, Raju C. Reddy and Anand K. Kondapi
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). A study of the topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes.
  2. (2009). An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles.
  3. (2008). Analyzing real-time PCR data by the comparative C(T) method.
  4. (1985). Anti-thrombotic effect of curcumin.
  5. (1976). Antioxidant activity of curcumin and related compounds.
  6. (1999). Antisense-mediated repression of DNA topoisomerase II expression leads to an impairment of HIV-1 replicative cycle.
  7. (2007). Bioavailability of curcumin: problems and promises.
  8. (1998). Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat.
  9. (2003). Curcumin as a DNA topoisomerase II poison.
  10. (2003). Curcumin inhibits ultraviolet light induced human immunodeficiency virus gene expression.
  11. (2000). Curcumin prevents adriamycin nephrotoxicity in rats.
  12. (2004). Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration.
  13. (2010). Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells.
  14. (2005). Haematological changes in adults recieving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d’lvoire.
  15. (1994). Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core.
  16. (1997). Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats.
  17. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.
  18. (1995). Inhibition of human immunodeficiency virus type-1 integrase by curcumin.
  19. (1993). Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes.
  20. (2005). Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.
  21. (1995). Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was recieving zidovudine.
  22. (1995). Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy.
  23. (1999). Modulation of surface transferrin receptors in lymphoid cells de novo infected with human immunodeficiency virus type-1.
  24. (1984). Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.
  25. (2010). Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry.
  26. (1973). Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent.
  27. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions.
  28. (2007). Polymeric nanoparticle-encapsulated curcumin (‘‘nanocurcumin’’): a novel strategy for human cancer therapy.
  29. (1985). Potential anticancer activity of turmeric (Curcuma longa).
  30. (1980). Preliminary study on antirheumatic activity of curcumin (diferuloyl methane).
  31. (1996). Protective role of curcumin against isoproterenol induced myocardial infarction in rats.
  32. (2007). Regulation of Topoisomerase II a and b in uninfected and HIV-1 infected Neuroblastoma and Astrocytoma cells: Involvement of Distinct nordihydroguaretic acid sensitive inflammatory pathways.
  33. (2005). Site specific alterations of adipose tissue mitochondria in 39-azido-39-deoxythymidine (AZT)-treated rats: An early stage in lipodystrophy.
  34. (2006). Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system.
  35. (2002). Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway.
  36. (1994). The influence of DNA and nucleosome structure on integration events directed by HIV integrase.
  37. (1993). The transferrin receptor: its diagnostic value and its potential as therapeutic target.
  38. (1993). Three inhibitors of type 1 human immunodeficiency virus long terminal repeatdirected gene expression and virus replication.
  39. (2002). Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen.
  40. (1991). Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.